Screening large numbers of urine samples for drugs of abuse is typically accomplished using immunoassays that allow for processing large numbers of samples without the requirement of sample preparation before analysis. Until fairly recently, screening of lysergic acid diethylamide (LSD) in urine samples could only be accomplished by the use of radioimmunoassays (RIA). Recently, new nonisotopic immunoassays have been developed for the screening of samples for LSD. These assays lend themselves to rapid, high-volume, automated analysis compared with RIA procedures. In order to evaluate the current commercially available assays, samples prepared at known concentrations were tested by each of the assays. In addition, samples from known use of LSD were tested and the performance of each of the assays compared. The assays examined in this study included RIA assays from Roche Diagnostics (Abuscreen) and Diagnostic Products (coat-a-count) and nonisotopic assays from Roche (OnLine), Behring (EMIT), Boehringer Mannheim (CEDIA), and STC (Microplate EIA). Assays that could readily be carried out in a semiquantitative mode (determining concentration based on a calibration curve) were evaluated as to their relative response to the samples tested. All of the assays evaluated identified all of the samples which confirmed positive by gas chromatography--mass spectrometry (GC-MS). Likewise, each of the assays identified some samples which did not confirm as positive by GC-MS.
Introduction
The abuse of lysergic acid diethylamide (LSD) has undergone a resurgence in recent years (1, 2) , as have several other drugs. LSD is of particular concern for several important reasons. It is a very potent drug, exerts numerous effects on the user, and is used at very low doses. Low doses coupled with the fact that only 1-2% of the drug is excreted intact makes detection of LSD use in urine drug testing programs very difficult (3) . The Department of Defense (DOD) has tested for the presence of LSD in urine for several years. Even with low cutoff concentrations used by the DOD, LSD is typically only positive for hours rather than days, which is seen with most other drugs of abuse (3) .
Along with a relatively difficult confirmation test, the analysis of LSD has been limited by the fact that the most commonly used screening tests used in urine drug testing did not have an assay available for LSD.
Radioimmunoassay (RIA), until recently, was the only imrnunoassay technique with sufficient sensitivity to identify LSD in urine samples at levels consistent with the typical use of this drug. Along with the RIA assays available from Roche Diagnostics (Abuscreen, Branchburg, NJ) and Diagnostic Products (coat-a-count, DPC, Los Angeles, CA), immunoassay kits are now available from Roche Diagnostics (OnLine), Behring Diagnostics (EMIT, San Jos~, CA), Boehringer Mannheirn (CEDIA, Concord, CA), and STC (Microplate EIA, Bethlehem, PA). All of these newly available assays are nonisotopic techniques that can be used on automated analyzers. The advantages of these assays include the lack of radioactive material with its accompanying handling and disposal requirements and the ability to fully automate, thereby minimizing analyst time during testing.
Performance of the STC assay has not previously been published at the time of this writing. Previous reports have focused on the nonisotopic CEDIA, EMIT, and OnLine assays and their performance compared with other assays using random urine samples of unknown origin (4) (5) (6) (7) (8) (9) (10) (11) . In contrast, the present study focuses on known controls and samples from controlled human and animal studies. Use of these samples limits issues of crossreactivity to unrelated compounds because of the controlled nature of the studies.
Materials and Methods

Materials
LSD was obtained from Radian (Austin, TX) and Alltech (Deerfield, IL). RIA reagents were obtained from Roche Diagnostics and DPC. Nonisotopic immunoassay reagents were obtained from Roche Diagnostics (OnLine), Behring Diagnostics (EMIT), Boehringer Mannheim (CEDIA) and STC (Microplate EIA). Control samples were obtained from the manufacturers if not provided as part of the kit. Several of these were used to assess the performance of the assays. Control samples were also prepared in the authors' laboratory from standard materials obtained from Radian and Alltech. Samples from previously conducted human (12) and animal (Papio cynocephalus) (13) studies were also used. These samples were from studies that involved the Reproduction (photocopying) of editorial content of this journal is prohibited without publisher's permission. administration of 4 and 2 pg/kg, respectively. Samples were stored at-20~ a temperature at which LSD has been shown to be stable (14) , until being thawed shortly before testing.
Methods
Irnmunoassays
Each of the immunoassays was evaluated by testing samples prepared at known concentrations of LSD. Between-run precision was determined by analysis of one 500 pg/mL sample in six different batches of samples each run on a different day. This number of replicates gave a 95% confidence with a power of 0.8 for determining the variability of the assays. The linearity of the assays was evaluated by analysis of samples containing various concentrations of LSD. Each of the assays were calibrated according to the manufacturers' instructions. Calibrators and controls from the EMIT and Roche assays were tested as controls by other assays to assess comparability of levels and performance of these samples. Samples from the controlled human and animal studies were tested with the OnLine, STC, CEDIA, EMIT, and RIA assays in a qualitative (positive/negative) mode and by STC, CEDIA, EMIT, and RIA assays in a quantitative mode.
RocheRIA. A 100-pL sample of urine was mixed with 200 pL of 125I-LSD reagent, 500 pL of second antibody reagent, and 200 pL of anti-LSD serum reagent. Following a 60-min incubation, the samples were centrifuged for 10 min, decanted, drained, blotted, and counted on a Micromedic 4/200 gamma counter (ICN, Costa Mesa, CA). The assay was calibrated using calibration standards at 0.0, 250, 500, and 1000 pg/mL LSD. Quantitation was based on a log-logit curve derived from these calibrators. Qualitative determination of positive and negative was determined by comparing the sample counts per minute (CPM) against the mean CPMs for the cutoff calibration sample (500 pg/mL). DPC R/A. A 100-pL sample of urine was mixed with 1 mL of ]25I-LSD reagent in the antibody-coated tube. Following a 2-h incubation, samples were decanted, drained, and blotted, and the tubes were counted on a Micromedic 4/200 gamma counter. The assay was calibrated using calibration standards at 0, 100, 250, 500, 1000, and 3000 pg/mL LSD. Quantitation was based on a log-logit curve derived from these calibrators. Qualitative determination of positive and negative was determined by comparing the sample CPM against the mean CPMs for the cutoff calibration sample (500 pg/mL).
OnLine. Reagent 1 (sample diluent and antibody reagent mixed 1:1) and Reagent 2 (micropartide reagent) were put in instrument containers and placed on the Hitachi 717 (Boehringer Mannheim, Indianapolis, IN). The 0.5-ng/mL calibrator (cutoff value) was set to zero by setting the S1 ABS to zero and K factor to 10,000. Ten sample cups containing calibrator were placed in sample positions and the absolute absorbances obtained. The mean of these absorbances was then entered in S1 ABS as the calibration number and the K factor set to -1000. The remainder of the samples were then analyzed. Samples reading less than zero were considered negative and samples reading greater than or equal to zero were reported as positive. The OnLine assay is designed to produce results that are qualitative only. Initial examination of the assay to produce semiquantitative results proved to be unsuccessful, and therefore, the assay was only evaluated qualitatively.
When evaluating the OnLine results, it should be noted the assay parameters used in this study are as recommended and used by the manufacturer in their assay directions and as described by McNally et al. (4, 5) . Subsequently, minor modifications have been recommended which have led to some performance changes in the assay (9) . These modifications result in an increased slope between the 0 pg/mL and the 250 pg/mL absorbances.
CEDIA
EMIT II (qualitative analysis). Reagent 1 and 2 (supplied ready for use) were put in instrument containers and placed on the Hitachi 717. The 0.5-0.OLO ng/mL calibrator (cutoff value) was set to zero by 0.o14 setting the $1 ABS to zero and K factor to 10,000 on One sample assayed did not yield a result; n = 5 for this set. nr, no result. The EMIT controls contained some substance that interfered with the CEDIA assay.
Solution (EA Reagent mixed with EA Reconstitution Buffer) were put in bar-coded bottles provided in the kit and placed on the Hitachi 911. At least 0.1 rnL of each calibrator and sample was pipetted into analyzer sample cups and placed into the appropriate position of the sample disk. The analyzer computer constructed a calibration curve from absorbance measurements of the standards using a four-parameter logit-iog fitting function. The assay was calibrated using calibration standards at 0, 500, 1500, and 3000 pg/mL LSD. Samples that gave a reading of < 500 pg/rnL were reported as negative, and those above 500 pg/mL that were reported as positive.
Microplate EIA. The stock enzyme conjugate was diluted as specified on the "Conjugate Dilution Instruction Sheet" supplied with each kit. The plate was washed once with wash buffer. A 25-pL sample of urine was pipetted into a microplate well followed by the addition of 100-pL of LSD antibody. The plate was incubated in the dark at room temperature for 60 rain. The plate was washed once, 100 pL of pre-diluted conjugate was added and allowed to incubate in the dark at room temperature for 30 rain. The plate was washed four times, 100 pL of substrate reagent was added, and the plate was incubated in the dark at room temperature for 30 rain. The reaction was stopped with the addition of 100 pL stopping reagent, and the absorbances read at 450 and 630 nm using a microplate reader. The assay was initially calibrated using calibration standards at 100, 250, 325, 500, 625, 1000, and 5000 pg/mL LSD. Quantitation was based on a log-log curve derived from these calibrators. See Results and Discussion section for alternative calibration curves evaluated. Qualitative determination of positive and negative was determined by comparing the sample absorbance with that of the cutoff calibrator (500 pg/mL).
Confirmation
Confirmation analysis of unknown specimens was accomplished by gas chromatography-tandem mass spectrometry (GC-MS-MS) in the laboratory of Dr. Rodger Foltz using-a previously described assay (15) .
Results and Discussion
All of the immunoassays used in this study were designed to provide qualitative results. Several of the manufacturers Positive  1526  >1000  >3000  3293  325  003  Positive  Positive  990  >1000  >3000  1817  542  004  Positive  Positive  1360  >1000  >3000  3025  522  005  Positive  Positive  665  >1000  >3000  764  712  006  Positive  Positive  >3000  >1000  >3000  >5000  757  007  Positive  Positive  >3000  >1000  >3000  2670  1773  008  Positive  Positive  >3000  >1000  >3000  >5000  1416  009  Positive  Positive  455  622  1010  602  108  010  Positive  Positive  217  299  670  256  38  011  Negative  Negative  84  78  140  0  16  012  Negative  Negative  0  8  130  0  0  013  Negative  Negative  56  0  90  91  NA t  014  Negative  Negative  105  0  90  437  5  015  Positive  Negative  84  9  0  1020  0  016  Positive  Positive  287  398  1700  413  NA  017  Positive  Positive  1100  >1000  >3000  4099  389  018  Positive  Positive  1163  >1000  >3000  576  371  019  Positive  Positive  1442  >1000  >3000  3568  377  020  Positive  Positive  >3000  >1000  >3000  >5000  639  021  Positive  Positive  2618  >1000  >3000  >5000  521  022  Positive  Positive  >3000  >1000  >3000  >5000  337  023  Negative  Negative  81  104  340  0  25  024  Positive  Negative  57  20  260  786  6  025  Negative  Negative  80  15  150  559  0  026  Positive  Positive  389  510  730  1007  19 
Use of an immunoassay in a semiquantitative mode can be useful in helping to determine dilution schemes for some analytes, but in the case of LSD, concentrations requiring dilution are typically not an issue. Because the antibodies are not absolute in their specificity, compounds which have similar structural features often cross-react. Given the fact that most of the LSD taken into the body is excreted as yet unidentified metabolites, cross-reactivity with an antibody targeted to LSD may be a useful tool in the isolation and ultimate identification of other metabolites. For this reason, the assays were evaluated for their quantitative response to LSD in controls and samples from controlled administration studies.
Variability of some of the assays was quite high (Table I ). This must be considered in light of the fact the assays were not designed for quantitative analysis. Knowing their performance, however, can help in the interpretation of results. This information can be helpful in comparison of immunoassay and GC--MS results, a common practice in drug-testing laboratories. It can also be helpful in evaluating the assay's ability to reveal the presence of LSD metabolites.
Evaluation of the curve performance of the STC assay was initially based on the examination of the r 2 value. Runs with an r 2 of > 0.95 were accepted. One of six runs was rejected based on these criteria and was repeated with acceptable results. Following analysis of all of the runs, calibration curves based on six, five, four, four (including a zero calibrator), and three points were evaluated in addition to the seven-point calibration used initially. The most consistent performance was seen with the three-point calibration using 0.25-, 0.5-, and 5.0-ng/mL calibrators. Although the average performance over six runs was very good for all calibration curves, evaluation of individual runs revealed more variability in almost all cases than was seen with the threepoint curve. In several instances, individual runs would have been rejected using calibration options other than the one noted previously. Twenty-eight urine samples from two human subjects who participated in a controlled LSD study were analyzed by each assay and the results reported as positive or negative and as a quantitative result by those assays which were capable of quantitative analysis. Results of these tests are shown in Table II . Samples that gave a reading equal to or greater than the cutoff based on the calibration procedures prescribed by the manufacturer were reported as positive. LSD concentrations were measured by GC-MS-MS and were classified as positive if they contained greater than or equal to 200 pg/mL (the current DOD GC-MS cutoff) of LSD. Volume restrictions prevented the analysis of two of these samples by GC-MS-MS and the ability to analyze the samples with the EMIT assay in a quantitative mode. Most of the samples showed some degree of cross-reactivity based on the calibration curves described previously ( Table II) . Samples that exceeded the linear range of the assay were reported as being greater than the upper limit of linearity. Samples that exceeded the upper limit of linearity were not diluted to determine actual concentration.
Comparison of immunoassay results with GC-MS--MS performance on the samples from human subjects revealed that all assays gave positive results for all samples that were positive by GC-MS-MS (> 200 pg/mL). This is an important finding, in that none of the assays gave CEDIA false-negative results with this group of samples. § Although this is important, minimizing the number of immunoassay positive samples that do not confirm 6 as positive is also a consideration. In that regard, the 6 DPC RIA assay matched the GC-MS-MS positive and 2 negative results with 100% agreement. The Roche 0 RIA had two samples that were positive that did not 0 confirm by GC-MS--MS at the administrative cutoff 6 but contained 108 and 19 pg/mL of LSD. The EMIT 6 and CEDIA assays gave identical results with three 6 0 samples that contained 108, 38, and 19 pg/mL of LSD o by GC-MS-MS. The Roche OnLine assay had five pos-0 itive samples containing 108, 38,19, 6, and 0 pg/mL of 2 LSD by GC-MS-MS. The STC assay had six samples nr identified as positive that contained 108, 19, 6, and nr three with 0 pg/mL of LSD by GC-MS (Table II) . nr
For the current methods of testing of LSD by nr immunoassay and confirmation of the parent LSD nr at greater than or equal to 200 pg/mL, the DPC RIA nr assay showed the best agreement between positive and negative samples from these human samples. All assays showed cross-reactivity to some samples that did not confirm as positive by GC-MS-MS. Given the fact these samples were from a controlled study in which LSD was administered, it seems Control I, Roche calibrators and controls; Control 2, controls prepared in the authors' laboratory using LSD standard from Radian; Control 3, controls prepared in the authors' laboratory using LSD standard from Alltech; Control 4, EMIT calibrators and controls. Samples analyzed by Roche Diagnostics personnel using assay parameters described in reference 9.
One sample assayed did not yield a result; n = 5 for this set. nr, no result. The EMIT controls contained some substance that interfered with the CEDIA assay.
likely that the positive immunoassay results for samples that contained little or no measurable parent LSD could be crossreacting with metabolites of LSD.
Results from the known control samples analyzed by each of the immunoassays are shown in Table III . The results indicated the performance of the assays in identifying control samples as positive or negative. Samples were analyzed in six separate runs on different days, and the qualitative results were recorded. As expected, most assays yielded both positive and negative results for samples containing 500 pg/mL. Each of the controls used was verified by GC-MS to be within acceptable limits of the target concentration; however, slight variations did exist. Looking at the measured quantitations (Table I) , it can be seen that the results typically showed averages reasonably close to the targeted concentrations. Looking at controls close to the cutoff concentration shows GC-~S-MS that several assays did very well in the proper identification of the controls as positive or negative. Positive Analysis of samples from a controlled animal Negative study are detailed in Table IV were not administered any other drugs at the time, the positive results that did not confirm are reasonably attributable to LSD metabolites that have not yet been identified. Further investigation must be conducted into the metabolism of LSD to allow for the identification of these metabolites. Those antibodies that indicated the presence of cross-reacting substances could be used for the immunoaffinity isolation of these metabolites that will allow for identification. It is clearly demonstrated from the controlled studies that the immunoassays react with metabolites associated with LSD. The advantages offered by the controlled studies are showing that cross-reacting substances exist in the samples and that there were not other drugs administered that might have lead to the cross-reactivity. A small number of random urine samples were evaluated as part of this study, although there was no systematic evaluation of interference or of assay performance with a large number of samples which do not contain LSD or LSD metabolites. Previous studies have addressed these issues and the present study should not be considered as evaluating all of the parameters important to the selection of a screening assay. It was noted in this study that one sample from a control subject was positive by two of the nonisotopic assays and, although negative by the other two, indicated the presence of cross-reacting substances. This sample contained no LSD, nor was it associated with LSD use. Therefore, investigation of LSD metabolites using random samples without the advantage of knowing the status of LSD use can result in substantial effort looking for unknown metabolites in samples that probably do not contain any. This has been one of the most limiting factors in the elucidation of LSD metabolites in recent years.
Conclusion
Analysis of urine samples for LSD can be accomplished with a number of different nonisotopic assays. All of the nonisotopic assays evaluated identified all of the urine specimens that confirmed positive by GC-MS-MS. Each of these assays also identified some samples that were not positive for LSD and, in some cases, contained no measurable LSD at all. Because these samples were all from known administrations of LSD, the positive results from the immunoassays could have been the result of cross-reactivity with as yet unknown LSD metabolites. Evaluation of known control samples, however, shows substantial variability among some of the assays, which leads to not identifying all controls with > 500 pg/mL of LSD and identifying some with < 500 pg/mL of LSD as positive. This information should be considered in selection of the assay best suited for a laboratory's analytical needs.
